Incanthera Secures Commercial Skincare Deal & £1M Fundraise

18th December 2023 - 12:32 pm

ImmuPharma PLC (LSE AIM: IMM), the specialist drug discovery and development company, is delighted to highlight the announcement issued this morning by Incanthera plc (“Incanthera”), the dermatology and oncology specialist, in which ImmuPharma currently holds a 12.7% shareholding.

Within the announcement, Incanthera announces a significant commercial skincare deal with Marionnaud (part of the A.S. Watson Group) initially across Europe and further roll outs in Asia. It confirmed that this deal is expected to generate significant revenues and profitability for Incanthera, in 2024 and beyond.

In conjunction Incanthera announces that it has concluded a successful fundraise of £1,000,000, with new and existing institutional investors which was oversubscribed, and is priced at £0.07, a premium of 11.1% to the mid-market price at the close of trading on Friday 15 December 2023.

Incanthera trades on Aquis Stock Exchange (“AQSE”) under the ticker (AQSE:INC). For full details of the announcement, please visit Incanthera’s website:

Commenting on Incanthera’s announcement, Dr Tim Franklin, COO of ImmuPharma said: “As a major shareholder in Incanthera, we are delighted with this significant milestone, which highlights the enormous opportunities within Incanthera’s revolutionary skincare range.”

To download this announcement click here

Share this article